3 completed, 2 terminated. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Terminated 2 |
Follow Enyo Pharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vonafexor in Patients With Impaired Renal Function and Suspected MASH (Metabolic Dysfunction-associated Steatohepatitis) Vonafexor low dose, Vonafexor high dose - Chronic Kidney Disease Stage 2, Chronic Kidney Disease Stage 3 | Phase 2 | Terminated | Enyo Pharma | 10 | 2025-07-01 | 2026-04-23 |
| Vonafexor ALPort Syndrome Efficacy & Safety TRIAl-1 (ALPESTRIA-1) Vonafexor - Alport Syndrome | Phase 2 | Completed | Enyo Pharma | 26 | 2024-08-01 | 2026-02-09 |
| A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With Entecavir EYP001a, Entecavir, Pegylated interferon alpha2a - Hepatitis B, Chronic | Phase 2 | Completed | Enyo Pharma | 20 | 2020-05-25 | 2022-08-25 |
| Study of EYP001a to Assess Its Safety and Anti-viral Effect in CHB Patients in Combination With NA (ETV or TD) EYP001a, Placebo, Nucleotide analogue (Entecavir or Tenofovir Disoproxil) - Hepatitis B, Chronic | Phase 2 | Terminated | Enyo Pharma | 26 | 2020-05-12 | 2022-11-02 |
| Safety, Tolerability, Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH) Vonafexor, Placebo - Non-alcoholic Steatohepatitis | Phase 2 | Completed | Enyo Pharma | 120 | 2019-01-30 | 2023-05-06 |
Hepatitis B, Chronic (2) · Liver Diseases (1) · Nephritis, Hereditary (1) · Non-alcoholic Fatty Liver Disease (1) · Renal Insufficiency, Chronic (1)
entecavir (2) · Tenofovir (1) · peginterferon alfa-2a (1)
France (2) · Hong Kong (2) · South Korea (2) · United States (2) · Australia (1) · Belgium (1) · Germany (1) · Poland (1) · Puerto Rico (1) · Spain (1) · Taiwan (1) · United Kingdom (1)
2018 (1), 2023 (1)